Much has been discussed around risk-based monitoring, changing the monitoring aspects during clinical development trials, highlighting the impact on roles, patient safety, data quality and cost. But where is this leading Biopharma and medical device development? What might clinical product development look like in 3 years? 5 years?
Dan White has been leading risk-based deployments for over 12 years and will share his views on the next-generation of changes to the evolution of product development. These
views include how to identify risks from the protocol design and mitigate risk through execution, and how new technologies facilitate real-time data review by seamlessly integrating data, systems and processes, and therapeutic expertise. With new data integration, how triggers and alerts initiate the right action at the right time for safe, efficient, and high quality trial management, enabling users to drill down into data to gather insights, recognize current and emerging trends, and, make faster, more informed decisions that impact study quality, efficiency and productivity.
From this webinar, you will hear:
- How technology is enabling and driving this evolution
- What roles will be critical to optimize these changes
- A vision on how this impacts the future of product development
Register Now to hear an open dialog with an industy expert on the changes occurring now, and what the future looks like, for clinical product development. Learn the answers to questions like:
- What is on the horizon to drive efficiency further, shortening timelines and improving quality?
- How can investigator sites leverage technology advancements to streamline their processes?
- How can clinical development become more efficient with predictable trial execution outcomes?
Dan White, Vice President, Global Operations, Quintiles
Dan White leads Quintiles’ centralized monitoring and endpoint adjudication groups. In this position, Dan leads over 26 centralized monitoring locations around the world, including centers in Latin America, Eastern/Western Europe, Australia, South Africa, India, and the US (largest center). Dan has been with Quintiles over 13 years and is Quintiles subject matter expert on risk-based monitoring, working with sponsors on the implementation of risk-based monitoring across the Quintiles organization.
Who Should Attend?
EVPs, VPs, Directors, Heads, Managers, Principal Scientists of:
- Clinical R&D
- Clinical Operations (Clinical Project Leads, Clinical Program Managers, Therapeutic Heads, Clinical Data Managers, Pharmacovigilance Scientist)
- Regulatory Affairs
- Medical Affairs
- Outsourcing Management
Quintiles is the only fully integrated bioPharmaceutical services company offering clinical, commercial, and consulting solutions worldwide. The Quintiles network of more than 27,000 engaged professionals in 59 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bioPharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.